Equity/Index & Cross Asset Volatility Specialist, Cameron Design

Jay Cameron

Equity/Index & Cross Asset Volatility Specialist

Cameron Design

We specialize in financial products and volatility. Our strategies balance speed, data, and risk control to capture opportunities across global markets. Our research leverages AI and data analytics to continuously refine our algorithms and adapt to evolving market dynamics.

Event-Driven

TSURUHA HOLDINGS INC. is a holding company which manages subsidiaries that operate drug stores in Hokkaido and the Tohoku area.  The Company's product line includes drugs, cosmetics, and household utensils.

<ul>
<li>The Tsuruha-Welcia merger creates Japan's largest drugstore alliance, poised for long-term growth and market dominance, driven by an expected JPY 50B in synergies over three years.</li>
<li>A two-step corporate action—share exchange (Dec 1, 2025) followed by an Aeon TOB—provides structural certainty and strategic backing, securing the combined entity's market leadership.</li>
<li>These catalysts establish a large market leader in the consumer staples space, suggesting a timely opportunity to gain exposure to the new entity.</li>
</ul>


The Tsuruha-Welcia merger creates Japan's largest drugstore alliance, poised for long-term growth and market dominance, driven by an expected JPY 50B in synergies over three years.
A two-step corporate action—share exchange (Dec 1, 2025) followed by an Aeon TOB—provides structural certainty and strategic backing, securing the combined entity's market leadership.
These catalysts establish a large market leader in the consumer staples space, suggesting a timely opportunity to gain exposure to the new entity.


Tsuruha-Welcia Merger to Form Biggest Drugstore Alliance, +Aeon TOB

Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

Kyowa Hakko Kirin Co.,Ltd. develops, manufactures, and markets pharmaceuticals. The Company's products include a protein produced by genetic recombination technology, an anti-anemia agent that attaches new sugar chains through partial modification of the amino acid sequence of human erythropoietin (EPO), and a glycoprotein, human erythropoietin.

<ul>
<li>
<a href="https://www.smartkarma.com/entities/kyowa-kirin-co-ltd" target="_blank" data-smartkarma-citation="entities:18055:1" rel="noopener">Kyowa Kirin Co Ltd (4151 JP) </a>announced that ziftomenib is now commercially available in the U.S. Company will be eligible for 50% profit sharing from drug sales in the U.S.</li>
<li>Rocatinlimab, under Phase 3 trials, represents a potentially novel upstream approach for the management of mild to severe atopic dermatitis. It is also undergoing Phase 3 trials for Prurigo nodularis.</li>
<li>2026 will be an inflection point. Ziftomenib results will slowly fall in place. Positive results of rocatinlimab and new manufacturing facilities has potential to play out in long term.</li>
</ul>



Kyowa Kirin Co Ltd (4151 JP) announced that ziftomenib is now commercially available in the U.S. Company will be eligible for 50% profit sharing from drug sales in the U.S.
Rocatinlimab, under Phase 3 trials, represents a potentially novel upstream approach for the management of mild to severe atopic dermatitis. It is also undergoing Phase 3 trials for Prurigo nodularis.
2026 will be an inflection point. Ziftomenib results will slowly fall in place. Positive results of rocatinlimab and new manufacturing facilities has potential to play out in long term.


Kyowa Kirin (4151 JP): Ziftomenib Approval and Commercialization A Positive, What Lies Ahead?

Japanese Equity Specialist, Ortus Advisors

Andrew Jackson

Japanese Equity Specialist

Ortus Advisors

Thematic (Sector/Industry)

<ul>
<li>Sandisk up as NAND prices continue to surge, expect Kioxia to run also with recent Bain sale cleared.</li>
<li>JP factory automation names surged yesterday, but there are likely more gains yet as the next leg for AI.</li>
<li>Quantum names all strong on good numbers, but will Socionext catch on this time?</li>
</ul>


Sandisk up as NAND prices continue to surge, expect Kioxia to run also with recent Bain sale cleared.
JP factory automation names surged yesterday, but there are likely more gains yet as the next leg for AI.
Quantum names all strong on good numbers, but will Socionext catch on this time?


Japan Morning Connection: Memory Back on and Micron Steps Back from Consumer to Focus on Enterprise

Japan Specialist

Mark Chadwick

<ul>
<li>U.S. stocks were mixed as soft labor data and tech gains boosted hopes for Fed easing, despite corporate layoffs and policy uncertainty, with investors awaiting Friday’s key PCE inflation report.</li>
<li>Tech outperformed as Meta jumped on planned metaverse cutbacks, Nvidia gained over 2%, and Salesforce rose on a stronger outlook.</li>
<li>Japanese automakers rallied after Trump scrapped Biden’s fuel-efficiency rules, boosting prospects for conventional powertrains and benefiting Subaru’s U.S.-focused lineup. </li>
</ul>


U.S. stocks were mixed as soft labor data and tech gains boosted hopes for Fed easing, despite corporate layoffs and policy uncertainty, with investors awaiting Friday’s key PCE inflation report.
Tech outperformed as Meta jumped on planned metaverse cutbacks, Nvidia gained over 2%, and Salesforce rose on a stronger outlook.
Japanese automakers rallied after Trump scrapped Biden’s fuel-efficiency rules, boosting prospects for conventional powertrains and benefiting Subaru’s U.S.-focused lineup. 


Ohayo Japan | Markets Mixed, Rate-Cut Bets Rise, Tech Outperforms

External broker reports(aggregated public sources), Mizuho

Mizuho

External broker reports(aggregated public sources)

Mizuho Bank is a leading global bank with one of the largest customer bases in Japan, and an extensive international network covering financial and business centers around the world. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

FX & Rates

The Japanese yen is the official currency of Japan. 

<ul><li>USD/JPY continued to rise in November</li><li>Reflationary expectations are strengthening under the Takaichi administration, thanks also to the unrestrained rhetoric of those around the prime minister</li><li>Unless there is a clear shift in the government and ruling party’s fiscal and monetary policies, market participants have little reason to stop selling JPY and JPY­ denominated bonds</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

USD/JPY continued to rise in NovemberReflationary expectations are strengthening under the Takaichi administration, thanks also to the unrestrained rhetoric of those around the prime ministerUnless there is a clear shift in the government and ruling party’s fiscal and monetary policies, market participants have little reason to stop selling JPY and JPY­ denominated bondsContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Japan
Insights on Japan

Tsuruha-Welcia Merger to Form Biggest Drugstore Alliance, +Aeon TOB

Aeon’s partial TOB for Tsuruha Holdings is targeting 43,240,590 shares at 2900 per share, or around JPY 125B notional running from Dec 3 to Jan 6. ...

Jay Cameron

Kyowa Kirin (4151 JP): Ziftomenib Approval and Commercialization A Positive, What Lies Ahead?

Kyowa Kirin's ziftomenib is now commercially available in the U.S. Rocatinlimab shows promise for atopic dermatitis and Prurigo nodularis in Phase...

Tina Banerjee

Japan Morning Connection: Memory Back on and Micron Steps Back from Consumer to Focus on Enterprise

A rotation back towards larger cap names and Memory made a bit of a comeback after a few down days. Quantum computing names are back in favor after...

Andrew Jackson

Ohayo Japan | Markets Mixed, Rate-Cut Bets Rise, Tech Outperforms

Mixed U.S. stocks see tech gains and soft labor data fueling hopes for Fed easing, while Japanese automakers rally after Trump scraps fuel...

Mark Chadwick

Forex Medium-Term Outlook(Dec, 2025)

Reflationary expectations are strengthening under the Takaichi administration, thanks also to the unrestrained rhetoric of those around the prime...

Mizuho

Tsuruha-Welcia Merger to Form Biggest Drugstore Alliance, +Aeon TOB

Aeon’s partial TOB for Tsuruha Holdings is targeting 43,240,590 shares at 2900 per share, or around JPY 125B notional running from Dec 3 to Jan 6. ...

Jay Cameron

Kyowa Kirin (4151 JP): Ziftomenib Approval and Commercialization A Positive, What Lies Ahead?

​Kyowa Kirin's ziftomenib is now commercially available in the U.S. Rocatinlimab shows promise for atopic dermatitis and Prurigo nodularis in Phase...

Tina Banerjee

Japan Morning Connection: Memory Back on and Micron Steps Back from Consumer to Focus on Enterprise

A rotation back towards larger cap names and Memory made a bit of a comeback after a few down days. Quantum computing names are back in favor after...

Andrew Jackson

Ohayo Japan | Markets Mixed, Rate-Cut Bets Rise, Tech Outperforms

​Mixed U.S. stocks see tech gains and soft labor data fueling hopes for Fed easing, while Japanese automakers rally after Trump scraps fuel...

Mark Chadwick

Forex Medium-Term Outlook(Dec, 2025)

Reflationary expectations are strengthening under the Takaichi administration, thanks also to the unrestrained rhetoric of those around the prime...

Mizuho

Kyowa Kirin's ziftomenib is now commercially available in the U.S. Rocatinlimab shows promise for atopic dermatitis and Prurigo nodularis in Phase...

Mixed U.S. stocks see tech gains and soft labor data fueling hopes for Fed easing, while Japanese automakers rally after Trump scraps fuel...